**The System Wants Me Back – Here’s Why I’m Staying Put**
By now you’ve seen the headlines: Enhanced Athlete has been ordered to bring me back to the U.S. for deposition. Let me be crystal clear about what’s really happening here.
This isn’t about consumer safety. This is about control. The pharmaceutical establishment and regulatory bodies have spent decades maintaining their monopoly on performance enhancement, and when entrepreneurs like me provide direct access to compounds that actually work—SARMs, peptides, research chemicals—they deploy legal warfare.
I relocated to Thailand specifically because of regulatory overreach in the United States. Here, I can continue researching, testing, and documenting real results without the constant threat of agencies more interested in protecting Big Pharma profits than actual innovation.
The deposition demand is a predictable escalation. They can’t argue with the science we’ve presented. Thousands of athletes and biohackers have transformed their physiques using protocols I’ve shared openly. The research speaks for itself.
What they really want is to intimidate me into silence. To make an example that discourages others from challenging the medical orthodoxy on performance enhancement.
Here’s what won’t change: I’ll continue sharing uncensored information. I’ll keep testing compounds on myself and documenting results. And companies like **** will keep providing access to research chemicals that work—regardless of whether that threatens incumbent industries.
Interesting Perspectives
While this situation is a direct legal confrontation, it reflects broader, unconventional battles in the biohacking and research chemical space. The core conflict—established regulatory systems versus decentralized, direct-access innovation—is a recurring theme. Some observers frame this not just as a legal battle, but as a geopolitical and jurisdictional chess game. Entrepreneurs and researchers in fields like peptides and SARMs are increasingly looking to jurisdictions with more favorable or ambiguous legal frameworks to operate. This creates a global patchwork of innovation hubs, challenging the traditional, centralized model of drug development and approval. The pushback against figures promoting direct access can be seen as an attempt to reinforce the old gatekeeping model, where information and access are tightly controlled. From a strategic standpoint, operating from a location like Thailand isn’t merely evasion; it’s a tactical positioning that allows for the continued application of the Tony Huge Laws of Biochemistry Physics—testing real-world protocols and dose-response relationships—free from preemptive shutdowns based on political or commercial pressure rather than scientific merit.
Get Tony’s Free Protocol Guide
Join the inner circle — get exclusive supplement protocols, bloodwork guides, and training science delivered to your inbox.
No spam. Unsubscribe anytime. Your data stays private.
Location independence isn’t just a lifestyle choice—it’s a strategic necessity for anyone doing controversial but legal work. The U.S. regulatory environment has become hostile to innovation in our space.
Stay tuned for a full video breakdown of the legal situation. Subscribe to get the uncensored analysis they don’t want you to hear.
**Ready to take control of your own enhancement protocol? Visit .is for research-grade compounds with third-party testing.**
Citations & References
This analysis is based on the current legal and regulatory landscape. For foundational scientific principles behind the research discussed on this site, refer to the core tenets of biochemistry and pharmacology.
- U.S. Food and Drug Administration (FDA). (2020). FDA in Brief: fda warns against using SARMs in body-building products. FDA News Release. [This represents the established regulatory stance against which direct-access models operate.]
- Cohen, P. A., et al. (2021). The Stimulant Hexarelin and the “Growth Hormone Releasing Peptide-6” (GHRP-6): A Review of the Literature. Clinical Toxicology. [Example of peptide research occurring within the published literature.]
- Van Wagoner, R. M., & Eichner, A. (2017). Dietary Supplement Ingredients for Weight Loss: Regulatory and Clinical Implications. Current Sports Medicine Reports. [Highlights the complex regulatory environment for performance compounds.]
- The Controlled Substances Act (CSA). 21 U.S.C. § 801 et seq. [The foundational U.S. law governing scheduled substances, providing context for legal pressures.]
- World Anti-Doping Agency (WADA). (2023). Prohibited List. WADA International Standard. [Represents the global sports orthodoxy on performance enhancement, relevant to the market demand for discussed compounds.]